文献速递妇科

HER2阳性子宫内膜样子宫内膜癌具有独特的分子和免疫特征,与更活跃的免疫微环境和更差预后相关

HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
PubMed 文献 · Gynecol Oncol · 2023-03-30

研究分析2927例子宫内膜样子宫内膜癌(E-EMCA)肿瘤,HER2阳性率为5.47%。HER2阳性肿瘤在微卫星稳定(MSS)亚组中显示TP53突变和杂合性缺失增加、PTEN和CTNNB1突变减少,免疫检查点基因表达和免疫细胞浸润增加,MAPK通路激活评分升高,总生存更差。作者认为这些发现提示HER2和MAPK靶向治疗及免疫治疗可能使该人群获益。

要点

  • E-EMCA中HER2阳性率为5.47%,HER2状态非常规检测。
  • HER2阳性E-EMCA在MSS肿瘤中分子差异最明显,免疫微环境更活跃。
  • HER2阳性肿瘤MAPK通路激活评分升高,患者总生存更差。

核心结论

  • E-EMCA中HER2阳性对应独特分子景观,尤其在MSS肿瘤中。
  • HER2阳性肿瘤与MAPK通路激活增加及更活跃免疫微环境特征相关。
  • 作者认为这些发现提示HER2和MAPK靶向治疗及免疫治疗可能使该人群获益。

研究设计与样本

  • 分析来自Caris Life Sciences数据库的2927例E-EMCA肿瘤。
  • 在CLIA/CAP认证实验室(Caris Life Sciences,Phoenix,AZ)进行下一代测序、全外显子测序、全转录组测序和免疫组化。
  • HER2状态由从子宫浆液性癌外推的转录组 cutoff 确定。
  • HER2状态与患者结局的关系通过Kaplan-Meier分析确定。

主要发现

  • E-EMCA中HER2阳性检出率为5.47%。
  • 基于HER2状态的分子改变差异在MSS肿瘤中最明显,显示TP53突变和杂合性缺失增加、PTEN和CTNNB1突变减少。
  • HER2阳性肿瘤免疫检查点基因表达和免疫细胞浸润增加,尤其在MSS肿瘤中。
  • 所有HER2阳性肿瘤显示MAPK通路激活评分(MPAS)增加。
  • HER2阳性肿瘤患者总生存更差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: HER2 status is not routinely evaluated in endometrioid endometrial cancer (E-EMCA), though it is frequently overexpressed or amplified in high grade E-EMCA and uterine serous carcinoma. Defining characteristics and survival outcomes of HER2+ E-EMCA could reveal subsets of patients who may benefit from targeted therapies. METHODS: 2927 E-EMCA tumors from the Caris Life Sciences database were analyzed by next-generation sequencing and whole exome sequencing, whole transcriptome sequencing, and immunohistochemistry for molecular and genomic features in a CLIA/CAP-certified laboratory (Caris Life Sciences, Phoenix, AZ). HER2 status was determined by transcriptomic cutoff extrapolated from uterine serous carcinoma. The relationship between HER2 status and patient outcomes was determined by Kaplan-Meier analysis. RESULTS: HER2 positivity was detected in 5.47% of E-EMCA. Differences in molecular alterations based on HER2 status were most apparent in microsatellite stable (MSS) tumors, which displayed increased TP53 mutations and loss of heterozygosity (LOH) and decreased PTEN and CTNNB1 mutations. HER2+ tumors had increased immune checkpoint gene expression and immune cell infiltration, particularly among MSS tumors. All HER2+ tumors displayed increased MAPK pathway activation scores (MPAS) and patients with HER2+ tumors experienced worse overall survival. CONCLUSIONS: HER2 positivity in E-EMCA corresponds with a unique molecular landscape, particularly in MSS tumors. HER2+ tumors are also associated with increased MAPK pathway activation and exhibit features of a more active immune microenvironment. These findings suggest a potential benefit of HER2 and MAPK targeted therapies as well as immunotherapies in this patient population.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bruce SF, Wu S, Ribeiro JR, et al. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis. Gynecol Oncol. 2023. PMID: 37003074. doi:10.1016/j.ygyno.2023.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。